RTTNews | Sep 30, 2020 10:06AM EDT

10:05 Wednesday, September 30, 2020 (RTTNews.com) - ViralClear Pharmaceuticals, Inc. (BSGM) and Sorrento Therapeutics, Inc. (SRNE) have entered into an agreement to explore the synergistic potential of small molecules and antibodies combination therapies against COVID-19. ViralClear will contribute its oral antiviral Merimepodib which is currently in a phase 2 trial in combination with remdesivir to treat COVID-19. The agreement will allow for testing of merimepodib with neutralizing antibodies in the Golden Syrian hamster model of COVID-19.

The companies said, pending the outcome of these studies, the results might be presented to the FDA to support the initiation of a human clinical trial of the drug combination.

Read the original article on RTTNews ( https://www.rttnews.com/3132722/sorrento-to-explore-its-agents-in-combination-with-viralclear-s-merimepodib-against-covid-19.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved